ATE502121T1 - Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung - Google Patents

Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung

Info

Publication number
ATE502121T1
ATE502121T1 AT07777420T AT07777420T ATE502121T1 AT E502121 T1 ATE502121 T1 AT E502121T1 AT 07777420 T AT07777420 T AT 07777420T AT 07777420 T AT07777420 T AT 07777420T AT E502121 T1 ATE502121 T1 AT E502121T1
Authority
AT
Austria
Prior art keywords
lxr
sirt1
cholesterol
complex
modulates
Prior art date
Application number
AT07777420T
Other languages
English (en)
Inventor
Leonard Guarente
Monty Krieger
Xiaoling Li
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE502121T1 publication Critical patent/ATE502121T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07777420T 2006-06-06 2007-06-06 Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung ATE502121T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81115406P 2006-06-06 2006-06-06
PCT/US2007/013364 WO2007146023A1 (en) 2006-06-06 2007-06-06 Cholesterol-regulating complex of sirt1 and lxr and methods of use

Publications (1)

Publication Number Publication Date
ATE502121T1 true ATE502121T1 (de) 2011-04-15

Family

ID=38832070

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07777420T ATE502121T1 (de) 2006-06-06 2007-06-06 Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung

Country Status (10)

Country Link
US (1) US20100240029A1 (de)
EP (1) EP2024511B1 (de)
JP (1) JP2009539844A (de)
CN (1) CN101501220A (de)
AT (1) ATE502121T1 (de)
AU (1) AU2007258594A1 (de)
CA (1) CA2654701A1 (de)
DE (1) DE602007013213D1 (de)
ES (1) ES2362941T3 (de)
WO (1) WO2007146023A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
US20050136429A1 (en) * 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2013083431A1 (en) 2011-12-06 2013-06-13 Unilever Plc Skin anti-ageing composition
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
EP3068889B1 (de) * 2013-09-26 2019-04-17 Universitat Autònoma De Barcelona Gentherapiezusammensetzungen zur verwendung bei der vorbeugung und/oder behandlung von nicht alkoholbedingter fettleber
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
JP6607735B2 (ja) * 2014-10-16 2019-11-20 シスメックス株式会社 リポタンパク質のコレステロール取り込み能を測定する方法及び試薬キット
EP3242945B1 (de) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Einzelvektor-genkonstrukt mit insulin- und glucokinasegenen
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
CN108300774A (zh) * 2017-12-01 2018-07-20 苏州睿迈英基因检测科技有限公司 一种改进的开放染色质检测方法及其试剂盒和应用
MX2021015823A (es) * 2019-06-26 2022-02-03 Hoffmann La Roche Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1).
ES2948620T3 (es) 2019-07-10 2023-09-14 Masonic Medical Res Laboratory Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5744300A (en) * 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
US5919618A (en) * 1993-08-16 1999-07-06 Massachusetts Institute Of Technology Genes determining cellular senescence in yeast
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US6027883A (en) * 1994-03-30 2000-02-22 Mitokor Optimal procedure for isolation of mutant mitochondrial alleles
US5565323A (en) * 1994-03-30 1996-10-15 Mitokor Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
US5840493A (en) * 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
US5817782A (en) * 1994-06-03 1998-10-06 Research Corporation Technologies, Inc. Lag 1:gene for increasing the longevity of eukaryotes
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
US6291172B1 (en) * 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5705350A (en) * 1995-08-29 1998-01-06 Duke University Transcription factor complexes in senescent cells
WO1997041242A1 (en) * 1996-04-18 1997-11-06 Geron Corporation Senescence responsive transcriptional element
JPH109075A (ja) * 1996-06-20 1998-01-13 Hitachi Ltd 燃料供給装置及びこれを用いた内燃機関及び自動車
US6228583B1 (en) * 1997-08-04 2001-05-08 Massachusetts Institute Of Technology Assays for compounds which extend life span
US6835563B1 (en) * 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US7572575B2 (en) * 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
JP2005517007A (ja) * 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
US20030228607A1 (en) * 2002-04-15 2003-12-11 Wagner Brandee Lynn Screening method and modulators having an improved therapeutic profile
WO2004007691A2 (en) * 2002-07-17 2004-01-22 Sepro Corporation Herbicide-resistant plants, and polynucleotides and methods for providing same
US20050136429A1 (en) * 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
TWI238605B (en) * 2004-07-27 2005-08-21 Quanta Comp Inc Method for transmitting and receiving blue-tooth data and its apparatus
US20070099830A1 (en) * 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities

Also Published As

Publication number Publication date
CA2654701A1 (en) 2007-12-21
US20100240029A1 (en) 2010-09-23
JP2009539844A (ja) 2009-11-19
EP2024511A4 (de) 2010-02-03
CN101501220A (zh) 2009-08-05
ES2362941T3 (es) 2011-07-15
AU2007258594A1 (en) 2007-12-21
EP2024511B1 (de) 2011-03-16
DE602007013213D1 (de) 2011-04-28
WO2007146023A1 (en) 2007-12-21
EP2024511A1 (de) 2009-02-18

Similar Documents

Publication Publication Date Title
DE602007013213D1 (de) Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung
Tzouvelekis et al. Epigenetics in idiopathic pulmonary fibrosis
Wittig et al. Social support reduces stress hormone levels in wild chimpanzees across stressful events and everyday affiliations
Tang et al. PAH–DNA adducts in cord blood and fetal and child development in a Chinese cohort
Pierron et al. Effect of low-dose cadmium exposure on DNA methylation in the endangered European eel
Fuller‐Thomson et al. Making a link between childhood physical abuse and cancer: results from a regional representative survey
Milara et al. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke
Badiani et al. Tobacco smoking and cannabis use in a longitudinal birth cohort: evidence of reciprocal causal relationships
Weaver Towards sustainable mass tourism: Paradigm shift or paradigm nudge?
ATE552505T1 (de) Quantifizierbare interne referenzstandards für immunhistochemie und verwendung
Davies et al. Stressful city sounds: glucocorticoid responses to experimental traffic noise are environmentally dependent
MX2008011838A (es) Propagacion de celulas primarias.
Salom et al. Effects of demographic and weather parameters on COVID-19 basic reproduction number
FI20065294A0 (fi) Menetelmä ja laitteisto akkukennojen hoitamiseksi
BRPI0810666A2 (pt) Processo para detecção e classificação de defeitos de superfície em placas de lingotamento contínua.
Yang et al. Does environmental regulation improve public health? Evidence from China's Two Control Zones policy
Fang et al. Connexin43 hemichannels contribute to cadmium-induced oxidative stress and cell injury
BRPI0915974A2 (pt) métodos para modular funções biológicas, para tratar um animal sofrendo de um distúrbio ou doença, para alterar a expressão de pelo menos um peptídeo em um mamífero, e para triar um ou mais compostos de teste para habilidade para alterar a expressão de pelo menos um gene de interesse em um mamífero
D’Ambrosio et al. The Metropolis research. Experimental models and decision-making processes for the adaptive environmental design in climate change
EP2116613A4 (de) Verfahren zur messung von ldl-cholesterin und probenkörper zur messung con ldl-cholesterin
Hong et al. Urbanization and depressive symptoms among middle-aged and older adults in China
Caspeele Probabilistic evaluation of conformity control and the use of Bayesian updating techniques in the framework of safety analyses of concrete structures
EP2363498A4 (de) Verfahren zur quantitativen bestimmung von cholesterin in lipoproteinen mit geringer dichte, reagens für quantitative bestimmung und kit für quantitative bestimmung
WO2013077814A3 (en) Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
Bustaffa et al. Studies on markers of exposure and early effect in areas with arsenic pollution: Methods and results of the project SEpiAs. Epidemiological surveillance in areas with environmental pollution by natural or anthropogenic arsenic

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties